RSC Advances · 2023 · 25 citations · 49 references
MedicineMedicinal ChemistryOncologyCancer PharmacologyDrug DesignDrug DiscoveryMitotic InhibitorsTopoisomerase InhibitorsAnticancer ActivityAntiproliferative AgentsCancer Cell Proliferation InhibitionCell Cycle Arrest MechanismsDna Topoisomerase Ii InhibitionQuinoxaline ChemistryTopoisomerase Ii FunctionTopoisomerase Ii Inhibitors
= 33.7 ± 2.04 μM). Mechanistic studies revealed that compound 3b induced cell cycle arrest at the G1 transition and triggered apoptosis in MCF-7 cells, as evidenced by increasing the percentage of cells arrested in the G2/M and pre-G1 phases utilizing flow cytometric analysis and Annexin V-FITC/PI analysis. Moreover, compound 3b was found to substantially suppress topoisomerase enzyme activity in MCF-7 cells. Molecular modeling studies further supported the potential of compound 3b as a therapeutic candidate by demonstrating significant binding affinity to the active sites of both topoisomerase II and EGFR proteins. Taken together, the presented 2-substituted-quinoxaline analogues, especially compound 3b, show promise as potential candidates for the development of effective anti-breast cancer drugs.
49
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stefan Aebi, T. Davidson, Günther Gruber et al. · Annals of Oncology · 2010 · 2.9K citations · Full text
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fátima Cardoso, S. Kyriakides, Shinji Ohno et al. · Annals of Oncology · 2019 · 2.2K citations · Full text
Medicine, Oncology, Breast Oncology +13